TAVR as an Alternative to SAVR for Pure Native Aortic Regurgitation

Noble, Stéphane; Mauler-Wittwer, Sarah

doi:10.1016/j.cjca.2023.11.023

Cited by 7 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 Both balloon-expandable or self-expandable valves can be used for aortic regurgitation; however, there is more evidence behind balloon-expandable valves. 26 Although the calcified sinotubular junction could have been a concern, the delivery balloon of a 23 mm S3 valve is 20 mm, and the simulated implanted height spared the calcified junction, so we decided to go with a balloon-expandable system.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Transcatheter Aortic and Mitral Native Valve Replacement: A Step-by-Step Procedural Approach

Farjat-Pasos,

Kalavrouziotis,

Beaudoin

et al. 2024

Structural Heart

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Simultaneous Transcatheter Aortic and Mitral Native Valve Replacement: A Step-by-Step Procedural Approach

Farjat-Pasos,

Kalavrouziotis,

Beaudoin

et al. 2024

Structural Heart

View full text Add to dashboard Cite

“…

…”

mentioning

confidence: 99%

“…BSA: body surface area BMI: body mass index, COPD: chronic obstructive pulmonary disease;1 It was done by Student's T-test.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Early Results of Supra-Annular and IntraAnnular Aortic Valve Replacement in Isolated Aortic Valve Replacement

Beyazal

2024

Sisli Etfal

View full text Add to dashboard Cite

S urgical aortic valve replacement (AVR) is the gold standard for the treatment of aortic stenosis and regurgitation. [1,2] In AVR, the location where the valve is placed is as important as the features of the prosthetic valve. The implanted valve orifice area is important in the regression of left ventricular (LV) hypertrophy. The smaller effective orifice area (EOA) resulting from small prosthesis implantation may be associated with higher patient-prosthesis mismatch (PPM) and less regression of LV hypertrophy. [3] Instead of intra-annular valve implantation in patients with small an-Objectives: This study aims to compare the early results of patients who underwent isolated aortic valve replacement (AVR) with supra-annular and intra-annular AVR. Methods: Between 2013 and 2019, 113 patients (77 males; mean age 57.8±16.36 years) who underwent isolated AVR were evaluated. The patients were divided into two groups those who underwent supra-annular (n=59) and intra-annular (n=54) AVR. The most commonly used valves in surgeries

show abstract

Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study

Jin,

Zhang,

Zhou

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

BackgroundTranscatheter aortic valve implantation (TAVI) is a well‐established intervention for severe aortic valve stenosis. However, its application for severe aortic regurgitation (AR) is still under evaluation. This study aims to present the 3‐year follow‐up outcomes of the J‐Valve system in managing severe AR.AimsThe aim of this study was to evaluate the mid‐term efficacy and durability of the J‐Valve system in the treatment of severe AR and to provide new information on this intervention.MethodsIn this retrospective, single‐center study, we evaluated the prognostic outcomes of patients with AR, who underwent treatment with the J‐Valve system at Nanjing Drum Tower Hospital. Consecutive patients who were treated with the J‐Valve were included in the analysis. The study focused on the echocardiographic follow‐up to assess the effectiveness and durability of the J‐Valve system in managing AR.ResultsFrom January 2018 to December 2022, 36 high‐risk AR patients treated with the J‐Valve system had a procedural success rate of 97.2%, with one case requiring open‐heart surgery due to valve displacement. Significant improvements were observed in left ventricular diameter (from 63.50 [58.75–69.50] mm to 56.50 [53.00–60.50] mm, p < 0.001) and left atrial diameter (from 44.00 [40.00–45.25] mm to 39.00 [36.75–41.00] mm, p = 0.003) postsurgery. All patients completed the 1‐year follow‐up, with an overall mortality rate of 2 out of 36 (5.6%). Among the surviving patients, there was one case of III° atrioventricular block and one case of stroke, both occurring within 90 days postsurgery. After a 3‐year follow‐up, 15.0% of patients had mild or moderate valvular regurgitation, with no cases of moderate or severe paravalvular leak. Additionally, 89.5% of patients were classified as New York Heart Association class I or II, showing significantly enhanced cardiac function.ConclusionThe J‐Valve system has shown positive therapeutic outcomes in treating AR, with notable effectiveness in managing the condition and significant improvements in heart failure symptoms and cardiac remodeling. However, due to the limited sample size and partial follow‐up data, it is important to emphasize the need for further research with comprehensive long‐term follow‐up, to fully validate these results.

show abstract

TAVR as an Alternative to SAVR for Pure Native Aortic Regurgitation

Cited by 7 publications

References 42 publications

Simultaneous Transcatheter Aortic and Mitral Native Valve Replacement: A Step-by-Step Procedural Approach

Simultaneous Transcatheter Aortic and Mitral Native Valve Replacement: A Step-by-Step Procedural Approach

Comparison of the Early Results of Supra-Annular and IntraAnnular Aortic Valve Replacement in Isolated Aortic Valve Replacement

Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study

Contact Info

Product

Resources

About